Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program Continues Following Positive Initial Data Topical Rapamycin Development Programs Advancing Using Two Proprietary Delivery Technologies ASHBURN, Va., July 29, 2025 (GLOBE NEWSWIRE)… Read More..
Study demonstrates a correlation between peripheral pro-inflammatory mechanisms, particularly monocytes and oxidative stress, in the progression and severity of Parkinson’s Disease (PD); In addition to PD, Coya has sponsored research demonstrating the potentially critical role of inflammation in the progression and severity of other diseases, such as amyotrophic lateral sclerosis… Read More..
Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE PARK, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for… Read More..